ImmuPharma plc (ALIMM.BR)

0.089 €

0.00 (-%)
Rating:
Recommendation:
-
Symbol ALIMM.BR
Price 0.089 €
Beta 1.258
Volume Avg. 0.00M
Market Cap 25.022M
Shares () -
52 Week Range 0.07-0.177
1y Target Est -
DCF Unlevered ALIMM.BR DCF ->
DCF Levered ALIMM.BR LDCF ->
ROE -97.94% Strong Sell
ROA -90.29% Strong Sell
Operating Margin -
Debt / Equity 33.32% Neutral
P/E -
P/B 1.88 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. Dimitri F. Dimitriou
Healthcare
Biotechnology
Brussels

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity, anti-infectives, metabolism, and cancer. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology; and BioGlucagon a therapy for low sugar events in diabetes. ImmuPharma plc has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. The company was founded in 1999 and is headquartered in London, the United Kingdom.